In breast cancer patients, several immune checkpoints, including programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), seem to be related to the specific tumour subtype, but the relationship between expression and prognosis remains unclear [8,9,10]. Here, PDCD1 is linked to neoplasm.